All Studies Meta Analysis

Crying wolf in time of Corona: the strange case of ivermectin and hydroxychloroquine. Is the fear of failure withholding potential life-saving treatment from clinical use?

Nardelli et al., Signa Vitae, doi:10.22514/sv.2021.043

Mar 2021

Post
Facebook

Source PDF All Studies Meta AnalysisMeta

Download Image

Ivermectin for COVID-19

4th treatment shown to reduce risk in August 2020, now with p < 0.00000000001 from 105 studies, recognized in 23 countries.

Lower risk for mortality, ventilation, ICU, hospitalization, recovery, cases, and viral clearance.

No treatment is 100% effective. Protocols combine treatments.

5,100+ studies for 111 treatments. c19ivm.org

Meta analysis of RCT mortality results showing RR 0.19, p < 0.00001.

7 meta analyses show significant improvements with ivermectin for mortality1-6, hospitalization7, recovery3, and cases3.

Currently there are 105 ivermectin for COVID-19 studies, showing 47% lower mortality [34‑58%], 35% lower ventilation [17‑50%], 40% lower ICU admission [12‑58%], 34% lower hospitalization [21‑44%], and 81% fewer cases [71‑87%].

Important missing comments or errors? Let us know.

risk of death, 79.5% lower, RR 0.21, p < 0.001, treatment 14 of 703 (2.0%), control 57 of 620 (9.2%), NNT 14, odds ratio converted to relative risk.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

1. Bryant et al., Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines, American Journal of Therapeutics, doi:10.1097/MJT.0000000000001402.lww.com, doi.org.

2. Hariyanto et al., Ivermectin and outcomes from Covid-19 pneumonia: A systematic review and meta-analysis of randomized clinical trial studies, Reviews In Medical Virology, doi:10.1002/rmv.2265.wiley.com, doi.org.

3. Kory et al., Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19, American Journal of Therapeutics, doi:10.1097/MJT.0000000000001377.lww.com, doi.org.

4. Lawrie et al., Ivermectin reduces the risk of death from COVID-19 – a rapid review and meta-analysis in support of the recommendation of the Front Line COVID-19 Critical Care Alliance, Preprint, b3d2650e-e929-4448-a527-4eeb59304c7f.filesusr.com/ugd/593c4f_8cb655bd21b1448ba6cf1f4c59f0d73d.pdf.filesusr.com.

5. Nardelli et al., Crying wolf in time of Corona: the strange case of ivermectin and hydroxychloroquine. Is the fear of failure withholding potential life-saving treatment from clinical use?, Signa Vitae, doi:10.22514/sv.2021.043.signavitae.com, doi.org.

6. Zein et al., Ivermectin and mortality in patients with COVID-19: A systematic review, meta-analysis, and meta-regression of randomized controlled trials, Diabetes & Metabolic Syndrome: Clinical Research & Reviews, doi:10.1016/j.dsx.2021.102186.sciencedirect.com, doi.org.

7. Schwartz, E., Does ivermectin have a place in the treatment of mild Covid-19?, New Microbes and New Infections, doi:10.1016/j.nmni.2022.100989.sciencedirect.com, doi.org.

Nardelli et al., 11 Mar 2021, peer-reviewed, 8 authors.

This Paper Ivermectin All

{ 'indexed': {'date-parts': [[2022, 4, 5]], 'date-time': '2022-04-05T20:15:11Z', 'timestamp': 1649189711123}, 'reference-count': 0, 'publisher': 'MRE Press', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2021]]}, 'DOI': '10.22514/sv.2021.043', 'type': 'journal-article', 'created': {'date-parts': [[2021, 3, 12]], 'date-time': '2021-03-12T05:41:24Z', 'timestamp': 1615527684000}, 'source': 'Crossref', 'is-referenced-by-count': 2, 'title': 'Crying wolf in time of Corona: the strange case of ivermectin and hydroxychloroquine. Is the ' 'fear of failure withholding potential life-saving treatment from clinical use?', 'prefix': '10.22514', 'member': '26027', 'published-online': {'date-parts': [[2021]]}, 'container-title': 'Signa Vitae', 'original-title': [], 'link': [ { 'URL': 'https://oss.signavitae.com/mre-signavitae/article/20210508-344/pdf/3-4%20SV2021022602.pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 2, 24]], 'date-time': '2022-02-24T19:35:58Z', 'timestamp': 1645731358000}, 'score': 1, 'resource': {'primary': {'URL': 'https://www.signavitae.com/articles/10.22514/sv.2021.043'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021]]}, 'references-count': 0, 'URL': 'http://dx.doi.org/10.22514/sv.2021.043', 'relation': {}, 'subject': [], 'container-title-short': 'SV', 'published': {'date-parts': [[2021]]}}

Download Image

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0